The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial
| Autor: | Shao-Tsu Chen, Tsu-Wang Shen, Yi-Lin Hsiao, Shaw-Ji Chen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Cross-Cultural Comparison Male medicine.medical_specialty Adolescent Beck Anxiety Inventory Population Aripiprazole Quinolones Piperazines Depressive Disorder Treatment-Resistant Young Adult Internal medicine medicine Clinical endpoint Humans Pharmacology (medical) Prospective Studies Psychiatry education education.field_of_study Depressive Disorder Major Dose-Response Relationship Drug business.industry Beck Depression Inventory Hamilton Rating Scale for Depression Middle Aged medicine.disease Thailand Antidepressive Agents Clinical trial Psychiatry and Mental health Major depressive disorder Drug Therapy Combination Female business medicine.drug Antipsychotic Agents |
| Zdroj: | Journal of clinical psychopharmacology. 32(1) |
| ISSN: | 1533-712X |
| Popis: | There is currently no published clinical trial on the safety and effectiveness of aripiprazole in Taiwanese patients with treatment-refractory major depressive disorder. We were interested in determining the applicability of current recommended doses of aripiprazole as an adjunct to antidepressant therapy in this population. We conducted a prospective, open-label nonrandomized, 4-week flexibly dosed (2.5-5 mg/d) trial with aripiprazole augmentation in 9 Taiwanese patients who had a history of nonresponse to at least 2 adequate courses of antidepressant therapy with different types of antidepressants. The primary end point for clinical effectiveness was mean change in the 17-item Hamilton Rating Scale for Depression at the end of the 4-week trial. Secondary end points for clinical effectiveness included mean change in Beck Depression Inventory and Beck Anxiety Inventory scores. The Systematic Assessment of Treatment Emergent Events-General Inquiry was used to assess adverse effects. All patients completed the trial and responded to treatment; the remission rate was 77.8%. The mean daily dose of adjunctive aripiprazole was 4.2 mg. Common treatment-emergent adverse events included insomnia and sedation (33.3%) and akathisia (22.2%). We found high effectiveness despite a lower mean daily dose of adjunctive aripiprazole (4.2 mg) when compared with previously reported findings; however, we also observed a higher frequency of treatment-emergent adverse effects. Additional studies are required to ascertain whether there are ethnic differences in the pharmacokinetics and/or pharmacodynamics of aripiprazole in treatment-refractory depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|